Loading
A phase 3 trial of Olomorasib, Pembrolizumab and Durvalumab in non-small-cell lung cancer, run by Eli Lilly and Company, now recruiting.
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT06890598 by Eli Lilly and Company, with 700 participants planned, started 2025-03-27 and due to reach its primary completion in 2029-05. Interventions recorded: Olomorasib, Pembrolizumab, Durvalumab and Placebo.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Olomorasib, Eli Lilly (incl. Loxo), KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors and the tag pipeline.
Shares Olomorasib, KRAS & RAS inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Olomorasib, Eli Lilly (incl. Loxo), KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors and the tag pipeline.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Pembrolizumab, Non-small-cell lung cancer and the tag pipeline.
Shares KRAS G12C-mutant non-small-cell lung cancer, KRAS & RAS inhibitors, Pembrolizumab, Non-small-cell lung cancer and the tag pipeline.
Shares Durvalumab, AstraZeneca, Non-small-cell lung cancer and the tag pipeline.
Shares Durvalumab, AstraZeneca, Pembrolizumab, Non-small-cell lung cancer and the tag pipeline.
Shares AstraZeneca, Pembrolizumab, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/